Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide plus LHRH agonist with salvage radiotherapy in high-risk post-prostatectomy biochemically relapsed prostate cancer
2017-000155-21Phase 3Active
- Sponsor
- Unicancer
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apalutamide in prostate adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoint: 5-year progression-free survival. Started Jan 2019; status: active.
02
Drugs
apalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2017-000155-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000155-21.